Coronavirus | RTI activist files plea against Covaxin in Bombay High Court

‘The company has not published the findings and data of their Phase 2 and ongoing Phase 3 trials in any paper’

Updated - January 16, 2021 07:35 pm IST

Published - January 16, 2021 06:25 pm IST - Mumbai:

Bharat Biotech’s COVAXIN vaccine is seen during the vaccination campaign in New Delhi on January 16, 2021.

Bharat Biotech’s COVAXIN vaccine is seen during the vaccination campaign in New Delhi on January 16, 2021.

A plea has been filed before the Bombay High Court on Saturday stating that as per the Drugs Controller General of India (DCGI), Bharat Biotech’s vaccine Covaxin has not been granted a full approval but a restricted use approval in clinical trial mode, while the company’s Phase-3 trials are ongoing and there is no data made available in the public domain by the DCGI for peer-review by independent scientists.

A Right to Information (RTI) activist Saket Gokhale filed a petition which says: “On January 3, 2021, DCGI issued a press release stating, “Covid-19 vaccines of M/s Serum Institute of India (named “Covishield”) and M/s Bharat Biotech (named “Covaxin”) have been approved for restricted use in emergency situation. The approval was granted based on the recommendations of the Subject Expert Committee of the Central Drugs Standard Control Organisation (CDSCO) a division of DCGI.”

“With reference to M/s Bharat Biotech’s vaccine “Covaxin”, the DCGI’s press release stated the company has generated safety and immunogenicity data in various animal species such as mice, rats, rabbits, Syrian hamster, and also conducted challenge studies on nonhuman primates (Rhesus macaques) and hamsters. All these data has been shared by the firm with CDSCO,” plea adds.

The petition contends, “The Subject Expert Committee reviewed the data on safety and immunogenicity of M/s Bharat Biotech’s “Covaxin” and recommended it for grant of permission for restricted use in emergency situation in public interest as an abundant precaution, in clinical trial mode, to have more options for vaccinations, especially in case of infection by mutant strains. The clinical trial ongoing within the country by the firm will continue.”

The plea says, “M/s Bharat Biotech have not published the findings and data of their Phase 2 and ongoing Phase 3 trials in any paper.” Mr. Gokhale had also filed a RTI query seeking a reply on, “Copies of safety, efficacy, and all other relevant data submitted by company Bharat Biotech International for its Covid-19 vaccine “Covaxin” to the Drugs Controller General India (DCGI) for approval.”

The RTI also sought a reply on the final report submitted by the subject expert committee (tasked to assess the COVID-19 vaccine approval applications of Covishield and Covaxin, amongst others) to the DCGI. However, Mr. Gokhale did not receive any response, hence the petition.

0 / 0
Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in

Comments

Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.